scholarly journals Breast MALT lymphoma and AL amyloidosis complicating Sjögren’s syndrome

2019 ◽  
Vol 12 (4) ◽  
pp. e227581 ◽  
Author(s):  
Nabil Belfeki ◽  
Salima Bellefquih ◽  
Anne Bourgarit

Marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) lymphomas of the breast with mammary amyloidosis are exceedingly rare entities. This report describes the case of women with long-standing Sjögren’s syndrome presenting with breast MALT lymphoma and amyloïd light-chain (AL) amyloidosis. Breast microcalcification needle biopsy made the positive diagnosis. This unusual finding should be kept in mind. It emphasises the need for careful clinical examination of nodes and extranodal organs supposedly affected in patients with autoimmune disease.

2021 ◽  
Author(s):  
Ke Lan ◽  
Fan Yang ◽  
Jun Wang ◽  
Jian Zhou

Abstract Background: Mucosa-associated lymphoid tissue (MALT) lymphoma rarely involves the thymus gland. About 5% of patients with Sjögren’s syndrome eventually develop lymphomas.Case presentation: A 52-year-old woman with Sjögren's syndrome and immunologic thrombocytopenic purpura was found to have a mediastinal tumor. Preoperative examination revealed the patient suffered from a severe thrombocytopenia and even had a rare blood group: O D+ (D+c+c+E+E+). Resection of the mediastinal tumor via video-assisted thoracic surgery (VATS) following thoroughly preparation including thrombocyte transfusion. Histopathologic examination and immunohistochemistry of the thymus tumor were both consistent with mucosa-associated lymphoid tissue (MALT) lymphoma. Conclusion:This rare case suggests that thymic MALT lymphoma can develop with an autoimmune disease such as Sjögren's syndrome, surgical resection of thymic tumor should be performed after careful preoperative preparation.


2007 ◽  
Vol 48 (6) ◽  
pp. 1222-1224 ◽  
Author(s):  
Masaru Kojima ◽  
Norihumi Tsukamoto ◽  
Yuri Miyazawa ◽  
Misa Iijima ◽  
Kazuhiko Shimizu ◽  
...  

Rheumatology ◽  
2020 ◽  
Vol 59 (Supplement_2) ◽  
Author(s):  
Kapil Halai ◽  
Ognjenka Savanovic-Abel ◽  
Timothy Howell

Abstract Background Amyloidosis is a disorder characterised by the misfolding of extracellular proteins. Patients with Sjögren’s syndrome frequently have a range of lung manifestations. Parenchymal nodular amyloidosis has been reported in association with Sjögren’s syndrome although occurrences are rare. Methods We present a 77 year old woman with a longstanding history of exertional breathlessness on a background of mild asthma since childhood, a cardiac pacemaker for atrial fibrillation and sick sinus syndrome. She has never smoked tobacco and has a good performance status. She presented with an episode of breathlessness and cough requiring hospital admission, receiving treatment for a lower respiratory tract infection. Results Chest X-rays had suggested two benign nodules in the right upper lobe which seemed to have progressed over the last ten years. Amongst her inpatient investigation, she underwent a CT-pulmonary angiogram which did not demonstrate a pulmonary embolism but found three lesions in the right upper lobe. The largest of the lesions measured 2.4cm in size and was suspicious for malignancy. A PET-CT scan showed two of these to be calcified lesions in the right upper lobe, and the other an irregular soft tissue density nodule with low-grade FDG uptake, suspicious of a primary bronchogenic tumour. Lung function showed mild airflow obstruction. Bronchoscopy and endobronchial ultrasound-guided biopsy did not yield a diagnosis. As surgery could be potentially curative, she underwent a right upper lobectomy and systematic nodal sampling. The histology on the lesions has shown abundant eosinophilic concretions with peripherally prominent foreign body giant cell reaction. This was congophilic and showed green birefringence. Further staining suggested AL amyloid. Histological appearances and the clinical picture seemed to represent parenchymal nodular amyloidosis. Further investigation revealed ANA was 1:640 speckled pattern and anti-Ro antibody positive. On further questioning, she reported sicca symptoms affecting eyes and mouth, fatigue and generalised arthralgia particularly affecting knees, ankles, wrist and shoulder. Schirmer’s test suggested severely dry eyes. A diagnosis of primary Sjögren’s was made and hydroxychloroquine was started. Conclusion Parenchymal nodular amyloidosis has been associated with Sjögren's syndrome but is a rare manifestation. However, there are other chronic inflammatory or haematological condition has been described. Parenchymal nodular amyloidosis is associated with multiple nodules, rarely a single nodule. Isolated pulmonary amyloidosis has four distinct patterns of presentation: diffuse alveolar septal, lymphatic, trachea-bronchial and nodule-parenchymal (typically found incidentally on routine imaging). These nodules remain stable over long periods of time. There is no curative treatment of nodular amyloid, but successful treatment has been documented with resection or laser therapy. In our patient, the presence of AL amyloidosis prompted us to investigate for an underlying cause and clinical features and immunological testing suggested primary Sjögren's and should be considered in the pulmonary manifestation of this condition. Disclosures K. Halai None. O. Savanovic-Abel None. T. Howell None.


Author(s):  
Simon Bowman ◽  
John Hamburger ◽  
Elizabeth Price ◽  
Saaeha Rauz

Sjögren's syndrome is a chronic, immune-mediated, condition of unknown aetiology characterized by focal lymphocytic infiltration of exocrine glands associated with dry mouth and eyes. It occurs in its own right (primary Sjögren's syndrome, pSS), or as a late feature of other rheumatic diseases such as rheumatoid arthritis, systemic lupus erythematosus or scleroderma (secondary Sjögren's syndrome). There is a strong female bias. pSS typically affects women in their middle years with an estimated prevalence of 0.1–0.6%. 75% of patients have anti-Ro and/or anti-La antibodies, often with raised immunoglobulin levels (hypergammaglobulinaemia). In patients without these antibodies the diagnosis can be confirmed by salivary gland biopsy. Treatment is generally symptomatic using artificial tears, saliva replacements/stimulants and good dental hygiene. Three-quarters of patients with pSS report significant fatigue with a negative impact on quality of life. This can be the most disabling symptom. Approximately 20% of patients develop systemic features including persistent salivary gland swelling, cutaneous vasculitis, peripheral neuropathy, interstitial lung disease, autoimmune cytopenias or renal tubular acidosis. Hydroxychloroquine and corticosteroids are the most widely used therapies for systemic features. There is a 44fold increased risk of mucosa-associated lymphoid tissue (MALT) B-cell lymphoma in pSS, typically affecting the salivary glands. On account of abnormalities in the B-cell system in pSS there is current interest in the use of anti-B-cell directed monoclonal antibodies to treat pSS and a number of clinical trials are in progress. This approach is already successfully in use for treating MALT lymphoma in pSS.


2007 ◽  
Vol 101 (1) ◽  
pp. 84-92 ◽  
Author(s):  
Spyros A. Papiris ◽  
Ioannis Kalomenidis ◽  
Katerina Malagari ◽  
George E. Kapotsis ◽  
Nikolaos Harhalakis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document